The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFIRINOX versus sequential 5-FU, oxaliplatin, and irinotecan-based regimens in patients with recurrent pancreatic cancer (rPDAC).
 
Hasan Rehman
Stock and Other Ownership Interests - Merck
 
Jeffrey Chi
No Relationships to Disclose
 
Nausheen Hakim
No Relationships to Disclose
 
Jyothi Jose
No Relationships to Disclose
 
Linda Moriarty
No Relationships to Disclose
 
Carol Lamont
No Relationships to Disclose
 
Wasif M. Saif
Consulting or Advisory Role - Celgene
Speakers' Bureau - Amgen; Celgene; Genentech; Ipsen; Lexicon; Novartis; Taiho Pharmaceutical
Research Funding - Celgene (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Lexicon; NanoCarrier; Pharmacyclics; Taiho Pharmaceutical (Inst)